Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mesothelioma; Pleura Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Orlando, Florida • Omaha, Nebraska • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
3
States / cities
Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Pleural Mesothelioma, Mesothelioma
Interventions
Cisplatin, Methotrexate, Gemcitabine, Lung Cancer Symptom Scale for Mesothelioma Questionnaire
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Cancer, Mesothelioma
Interventions
Alisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced May 21, 2026, 6:34 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
Biological
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
Interventions
CART-meso
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced May 21, 2026, 6:34 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM)
Interventions
Multipeptide vaccine S-588210
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions
Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced May 21, 2026, 6:34 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
PA-1-STK ovarian carcinoma vaccine, ganciclovir
Biological · Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced May 21, 2026, 6:34 PM EDT
Active, not recruiting Phase 1 Interventional Results available
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab, Radiation Therapy
Other · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Mesothelioma
Interventions
SCH 721015
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pleural Mesothelioma, Peritoneal Mesothelioma
Interventions
IMC-A12
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Mesothelioma
Interventions
Anetumab ravtansine (BAY94-9343), Vinorelbine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • Norwich, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced May 21, 2026, 6:34 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
Drug · Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pleural Mesothelioma
Interventions
Pembrolizumab, Cisplatin and Pemetrexed
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced May 21, 2026, 6:34 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Mesothelioma
Interventions
Cryotherapy, Control
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma
Interventions
Depsipeptide, Flavopiridol (alvocidib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 21, 2026, 6:34 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
tumor specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
GC1008
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced May 21, 2026, 6:34 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 6:34 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 21, 2026, 6:34 PM EDT